Spinal Muscular Atrophy (SMA) — Deal Benchmarks & Valuation
Market Analysis
Spinal Muscular Atrophy (SMA) is one of the most actively transacted indications in neurology licensing. Phase 1 deals for spinal muscular atrophy (sma) carry a median total deal value of $1.8B, with upfront payments ranging from $49M to $203M. The recommended deal structure allocates approximately 7% to upfront payments and 93% to milestones.
Milestone structures for spinal muscular atrophy (sma) deals allocate $841M to development milestones, $505M to regulatory milestones, and $336M to commercial milestones. Royalty rates range from 7.7% to 15.3% at the base tier, with tiered escalation reaching 11.7%-19.3% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for spinal muscular atrophy (sma) licensing?
What royalty rates are standard for spinal muscular atrophy (sma) deals?
How are spinal muscular atrophy (sma) deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.